Vir Biotechnology (VIR) Total Non-Current Liabilities (2018 - 2026)

Vir Biotechnology (VIR) has 9 years of Total Non-Current Liabilities data on file, last reported at $193.4 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities fell 22.36% year-over-year to $193.4 million; the trailing twelve-month figure through Mar 2026 stood at $193.4 million (down 22.36% YoY), and the FY2025 full-year result was $216.0 million, down 7.65% from the prior year.
• Total Non-Current Liabilities fell to $193.4 million in Q1 2026, from $216.0 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $867.2 million in Q1 2022 to a low of $193.4 million in Q1 2026.
• A 5-year average of $385.0 million and a median of $249.1 million in 2025 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities jumped 101.81% in 2022 and plunged 66.17% in 2024, its largest moves.
• Tracing VIR's Total Non-Current Liabilities over 5 years: stood at $699.2 million in 2022, then slumped by 56.68% to $302.9 million in 2023, then dropped by 22.79% to $233.9 million in 2024, then decreased by 7.65% to $216.0 million in 2025, then slipped by 10.45% to $193.4 million in 2026.
• Business Quant data shows VIR's Total Non-Current Liabilities at $193.4 million in Q1 2026, $216.0 million in Q4 2025, and $210.0 million in Q3 2025.